8-K
filed May 21, 2026, 4:30 PM ET
ticker DMAC
CIK 0001401040
other material
confidence high
sentiment neutral
materiality 0.15
DiaMedica shareholders re-elect all seven directors, approve auditor, exec compensation, and share increase
DiaMedica Therapeutics Inc.
- All seven incumbent directors re-elected; Daniel O'Connor received 5,130,879 votes withheld vs. ~200,000 for others.
- Baker Tilly US, LLP ratified as auditor for FY 2026 with 20,950,404 votes for and 578,926 against.
- Advisory vote on executive compensation approved: 9,928,381 for, 271,093 against, 149,163 abstain.
- Amendment to 2019 Omnibus Incentive Plan to increase shares by 3.5M approved: 9,693,413 for, 510,487 against.
- All proposals passed with broker non-votes of 11,180,693 on director election and other non-routine items.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
DiaMedica Therapeutics Inc. shareholders approved Election of Directors at the 2026-05-20 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-20
Exact text from the filing
Voting Proposal One - Election of Directors The seven director nominees, all incumbent directors, proposed by the Board were re-elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified based on the following voting results:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
DiaMedica Therapeutics Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-05-20 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-20
Exact text from the filing
Voting Proposal Two – Ratification of Independent Registered Public Accounting Firm The voting proposal to appoint Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 and authorize the Board to fix the Company’s independent registered public accounting firm’s remuneration was approved based on the following voting results:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
DiaMedica Therapeutics Inc. shareholders approved Amendment and Restatement of the Amended and Restated 2019 Omnibus Incentive Plan at the 2026-05-20 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-20
Exact text from the filing
Voting Proposal Four – Amendment and Restatement of the Amended and Restated 2019 Omnibus Incentive Plan The voting proposal to approve an amendment to the Company’s Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,500,000 shares was approved based on the following voting results:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
DiaMedica Therapeutics Inc. shareholders approved Advisory Vote to Approve of Executive Compensation at the 2026-05-20 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-20
Exact text from the filing
Voting Proposal Three – Advisory Vote to Approve of Executive Compensation The voting proposal to approve, on an advisory (non-binding) basis, the Company’s executive compensation was approved based on the following voting results:
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.